Zentalis Pharmaceuticals Stock Forecast - Price Action Indicator
| ZNTL Stock | USD 3.48 0.02 0.57% |
Zentalis Stock Forecast is based on your current time horizon. Although Zentalis Pharmaceuticals' naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Zentalis Pharmaceuticals' systematic risk associated with finding meaningful patterns of Zentalis Pharmaceuticals fundamentals over time.
Zentalis |
| Previous Price Action Indicator | Price Action Indicator | Trend |
| 0.15 | 0.005 |
| Check Zentalis Pharmaceuticals Volatility | Backtest Zentalis Pharmaceuticals | Information Ratio |
Zentalis Pharmaceuticals Trading Date Momentum
| On November 26 2024 Zentalis Pharmaceuticals Llc was traded for 3.48 at the closing time. The top price for the day was 3.55 and the lowest listed price was 3.38 . The trading volume for the day was 535.7 K. The trading history from November 26, 2024 had no short-term effect on price fluctuation. The trading date delta against the current closing price is 0.29% . |
Price Action Indicator (or PAIN) was developed by Michael B. Geraty and published in 'Futures' magazine in August 1997.
| Compare Zentalis Pharmaceuticals to competition |
Other Forecasting Options for Zentalis Pharmaceuticals
For every potential investor in Zentalis, whether a beginner or expert, Zentalis Pharmaceuticals' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Zentalis Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Zentalis. Basic forecasting techniques help filter out the noise by identifying Zentalis Pharmaceuticals' price trends.Zentalis Pharmaceuticals Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zentalis Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Zentalis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zentalis Pharmaceuticals by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Zentalis Pharmaceuticals Technical and Predictive Analytics
The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of Zentalis Pharmaceuticals' price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of Zentalis Pharmaceuticals' current price.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Zentalis Pharmaceuticals Market Strength Events
Market strength indicators help investors to evaluate how Zentalis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Zentalis Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Zentalis Pharmaceuticals stock market strength indicators, traders can identify Zentalis Pharmaceuticals Llc entry and exit signals to maximize returns.
| Accumulation Distribution | 25651.18 | |||
| Daily Balance Of Power | (0.12) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 3.47 | |||
| Day Typical Price | 3.47 | |||
| Price Action Indicator | 0.005 | |||
| Period Momentum Indicator | (0.02) |
Zentalis Pharmaceuticals Risk Indicators
The analysis of Zentalis Pharmaceuticals' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Zentalis Pharmaceuticals' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting zentalis stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 4.2 | |||
| Semi Deviation | 5.2 | |||
| Standard Deviation | 5.88 | |||
| Variance | 34.56 | |||
| Downside Variance | 29.17 | |||
| Semi Variance | 27.03 | |||
| Expected Short fall | (4.51) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Historical Fundamental Analysis of Zentalis Pharmaceuticals to cross-verify your projections. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.50) | Revenue Per Share 0.572 | Return On Assets (0.25) | Return On Equity (0.43) |
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.